Bladder cancer high prevalence, survival and recurrence rates combine to make it one of the most expensive cancers to treat and monitor. The gold standard diagnostic tool is combined cystoscopy and cytology which is costly and highly invasive requiring transurethral access and presenting the risk of important complications and discomfort to patients. Because clinical symptoms are not useful in predicting progression, surveillance requires frequent cystoscopies, on average in excess of 13 per patient following initial diagnosis and treatment. Fina Biotech offers a solution for the diagnosis of bladder cancer which is: